Suggested remit - To appraise the clinical and cost effectiveness of nivolumab within its marketing authorisation for unresectable, advanced oesophageal cancer when standard chemotherapy has failed.
Status In progress
Process STA
ID number 1249

Provisional Schedule

Expected publication 19 October 2018

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
06 February 2018 - 06 March 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
11 August 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance